GYRE

GYRE

USD

Gyre Therapeutics Inc. Common Stock

$7.290-0.180 (-2.410%)

Echtzeitkurs

Healthcare
Biotechnologie
Vereinigte Staaten

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$7.470

Hoch

$7.470

Tief

$7.250

Volumen

0.06M

Unternehmensfundamentaldaten

Marktkapitalisierung

662.1M

Branche

Biotechnologie

Land

United States

Handelsstatistiken

Durchschnittliches Volumen

0.09M

Börse

NCM

Währung

USD

52-Wochen-Spanne

Tief $6.11Aktuell $7.290Hoch $19

Ähnliche Nachrichten

GlobeNewswire

Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by

Mehr anzeigen
Gyre Therapeutics Announces Completion of Patient Enrollment in Phase 3 Clinical Trial of Pirfenidone Capsules for the Treatment of Pneumoconiosis
GlobeNewswire

Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025

SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics ("Gyre") (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems

Mehr anzeigen
Gyre Therapeutics to Present Results from Positive Phase 3 Clinical Trial Evaluating Hydronidone for the Treatment of Liver Fibrosis in Chronic Hepatitis B at AASLD—The Liver Meeting® 2025
Analyst Upgrades

Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16

Jefferies analyst Roger Song initiates coverage on Gyre Therapeutics with a Buy rating and announces Price Target of $16.

Mehr anzeigen
Jefferies Initiates Coverage On Gyre Therapeutics with Buy Rating, Announces Price Target of $16